PTCT PTC Therapeutics, Inc.
XNAS
59.97
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
PTCT
$59.97
—
Key stats
$59.97
- 52-Week Range
- $58.80 – $90.87
- YTD
- -21.85%
- IV Rank (30D)
- 17.51
- Straddle Price
- $5.67
- P/C Vol Ratio
- 1.53
- Market Cap
- $5.4B
- Open
- $64.75
- Day Range
- $59.64 – $65.34
- Volume
- 2,357,646
- Prev Close
- $64.46
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.99% |
| Beta vs SPY | 1.08 |
| Cost of Equity (CAPM) | 10.91% (VRP-adj) |
| WACC | 10.46% |
| Volatility Risk Premium | +33.9pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | 23.2% |
| Book / Price | -2.9% |
| Gross Margin (TTM) | 93.0% |
| FCF Margin (TTM) | -3.9% |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $65.57 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $62.27 |
| Bollinger Width / SMA20 | 15.8% (drives anchor stability) |
| Net Debt | $-0.5B |
| Market Cap | $6B |
Peers used for multiples: ACAD, ALKS, BIIB, GILD, LLY, NBIX, NTRA, VRTX
60-Day Conviction
78%
20-Day Fair Value
≈ by Nov 30, 2026
$60.00
α +0.0%
rank 42%
conviction
3%
40-Day Fair Value
≈ by Dec 29, 2026
$61.22
α +2.1%
rank 49%
conviction
68%
60-Day Fair Value
≈ by Jan 27, 2027
$61.66
α +2.8%
rank 39%
conviction
78%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 36.7× · 6 peers |
| Peer EV/EBITDA | $68.11 | 16% | median 28.6× · 7 peers |
| Peer P/B | n/a | 0% | median 5.4× · 8 peers |
| Peer P/S | $69.94 | 11% | median 5.5× · 8 peers |
| Market Anchor (SMA50) | $65.57 | 50% | stability 71% (BB-width) |
| Options Expected (B-L 30d) | $63.09 | 23% | 13 strikes · skew +0.15 |
As of 2026-10-30 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $5.4B
- Employees
- 991
- List Date
- 2013-06-20
- CIK
- 0001070081
- Headquarters
- Warren, NJ
- Homepage
- https://www.ptcbio.com
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -4.43% | -5.54% | 20.26% | -6.95% | 0.00% | -1.58% | 0.29% |
| Feb | 0.55% | -13.35% | -7.81% | 8.30% | 10.50% | -8.93% | -1.79% |
| Mar | -18.59% | 8.74% | 7.07% | -8.95% | -3.61% | 2.65% | -2.11% |
| Apr | -16.22% | -14.76% | 16.26% | 12.45% | 6.95% | -5.37% | -0.11% |
| May | -3.68% | -18.82% | -23.93% | 6.44% | -2.02% | 13.35% | -4.78% |
| Jun | 8.78% | 37.76% | -6.51% | -18.30% | 0.02% | 10.53% | 5.38% |
| Jul | -12.41% | 4.06% | -2.58% | 8.60% | 7.24% | -16.74% | -1.97% |
| Aug | 12.85% | 11.27% | -2.88% | 8.05% | -5.37% | 2.09% | 4.33% |
| Sep | -16.31% | -3.03% | -44.09% | 11.04% | 17.05% | -8.19% | -7.25% |
| Oct | 0.53% | -25.37% | -11.72% | 10.74% | 10.16% | -6.49%* | -3.69% |
| Nov | -5.49% | 9.97% | 24.77% | 8.43% | 26.59% | -- | 12.85% |
| Dec | 10.85% | -8.13% | 14.88% | -13.31% | -4.09% | -- | 0.04% |
| Total | -40.17% | -28.17% | -34.30% | 21.69% | 77.36% | -20.40% | -4.00% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $62.09
SMA 50: $65.36
SMA 200: $70.67
Current: $59.97
EMA 12: $62.07
EMA 26: $62.99
MACD: -0.9234 | Signal: 0.2849
BEARISH
ADX (14): 16.45
RANGE
+DI: 19.32
−DI: 30.91
Momentum Oscillators
RSI (14): 41.54
NEUTRAL
Stoch %K: 58.87
Stoch %D: 60.59
Williams %R: -82.11
Volume & Volatility
BB Upper: $65.27
BB Lower: $58.92
NEUTRAL
OBV: 60,903,742
Vol SMA 20: 1,086,018
Vol ROC: 197.80%
ATR: $2.39
True Range: $5.70
HV 20: 45.4%
HV 30: 43.5%
HV 60: 37.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-01T00:00:00 – 2026-10-30T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Recent positive news sentiment around product revenue and royalty acquisitions
- Technical indicators suggest a weak trend with a neutral momentum reading
Primary Risks:
- Potential for volatility to increase if earnings miss or regulatory issues arise
- Strong correlation with the market may amplify price movements
Investment Thesis: The stock is trading near its 200-day SMA, indicating a potential support level. However, the recent news headlines suggest that product revenue and royalty acquisitions are driving investor sentiment.
Recent News Sentiment Impact: Positive news headlines have contributed to a 4% price increase over the past week, with an aggregate sentiment score of 0.75 (Positive).
Technical Analysis
Trend Direction: Short-term: Neutral, Medium-term: Weak Trend, Long-term: Uptrend
Support/Resistance Levels: $73.98 (SMA 20), $77.28 (SMA 50), and $81.09 (Upper Bollinger Band)
Momentum Signals:
- RSI interpretation: Neutral (41.30)
- MACD signal: Bearish
- Bollinger Bands position: Neutral
Volume Analysis: Volume is trending downwards, indicating a potential decrease in buying pressure.
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines around product revenue and royalty acquisitions have dominated the market narrative.
Sentiment Assessment: Aggregate sentiment score of 0.75 (Positive)
Catalyst Identification: Upcoming earnings reports and potential regulatory changes could impact investor sentiment.
Market Narrative: The recent positive news has driven a short-term uptrend, but the technical indicators suggest a weak trend overall.
Risk & Volatility Assessment
Beta Interpretation: Low risk relative to market (beta 0.74)
Volatility Regime: Current volatility is low compared to historical levels.
Options Market Signals: IV rank: 7.7% (Low), Put/Call volume ratio: 5.36 (Bearish sentiment)
Downside Protection: Support level at $73.98 and potential for price to retest the SMA 200.
Market Context & Positioning
Sector Performance: Relative strength within the sector is moderate.
Institutional Activity: Institutional interest is low, with a decreasing volume flow.
Correlation Analysis: The stock has a strong correlation with the market (0.23), indicating that price movements will likely be amplified.
Relative Valuation: The stock is trading near its relative valuation level.
Key Levels & Action Items
Critical Price Levels: $73.98 (SMA 20) and $81.09 (Upper Bollinger Band)
Breakout/Breakdown Levels: Resistance at $77.28 (SMA 50) and potential for price to retest the SMA 200.
Time-Sensitive Catalysts: Upcoming earnings reports and regulatory changes could impact investor sentiment.
Risk Management: Stop-loss levels should be set at $67.87 (Lower Bollinger Band), and position sizing considerations should take into account the low risk relative to market (beta 0.74).
Note: This analysis is based on the provided data, and I will not make any buy/sell recommendations or provide specific trading advice.
Generated
News
All PTCT news →
Sephience revenue hit $182 million as the company raised full-year guidance.
Earnings History
23 of 26 under expected move
Avg Expected Move
12.74%
Avg Actual Move
7.08%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-11 | After-Close | 6.67% | 1.18% | 0.18x | Within |
| 2021-02-25 | After-Close | 12.59% | 3.46% | 0.27x | Within |
| 2021-05-04 | After-Close | 29.95% | 6.26% | 0.21x | Within |
| 2021-07-29 | After-Close | 12.03% | 0.24% | 0.02x | Within |
| 2022-01-10 | After-Close | 5.10% | 1.02% | 0.20x | Within |
| 2022-05-03 | After-Close | 10.74% | 2.66% | 0.25x | Within |
| 2022-08-04 | After-Close | 9.06% | 8.67% | 0.96x | Within |
| 2022-10-27 | After-Close | 6.28% | 13.73% | 2.19x | Exceeded |
| 2023-01-09 | After-Close | 9.01% | 6.63% | 0.74x | Within |
| 2023-04-27 | After-Close | 21.85% | 4.75% | 0.22x | Within |
| 2023-08-03 | After-Close | 9.00% | 3.99% | 0.44x | Within |
| 2023-10-26 | After-Close | 13.28% | 22.71% | 1.71x | Exceeded |
| 2024-01-08 | After-Close | 14.57% | 4.27% | 0.29x | Within |
| 2024-02-29 | After-Close | 17.67% | 13.34% | 0.75x | Within |
| 2024-04-25 | After-Close | 14.91% | 12.08% | 0.81x | Within |
| 2024-08-08 | After-Close | 15.95% | 3.57% | 0.22x | Within |
| 2024-11-07 | After-Close | 12.69% | 3.07% | 0.24x | Within |
| 2025-01-13 | After-Close | 8.63% | 5.09% | 0.59x | Within |
| 2025-02-27 | After-Close | 11.82% | 9.27% | 0.78x | Within |
| 2025-05-06 | Pre-Market | 11.44% | 10.97% | 0.96x | Within |
| 2025-08-07 | After-Close | 11.22% | 9.89% | 0.88x | Within |
| 2025-11-04 | After-Close | 14.36% | 5.98% | 0.42x | Within |
| 2026-01-12 | Pre-Market | 12.58% | 0.08% | 0.01x | Within |
| 2026-05-07 | After-Close | 11.28% | 14.27% | 1.27x | Exceeded |
| 2026-07-30 | After-Close | 14.37% | 9.94% | 0.69x | Within |
| 2026-10-29 | After-Close | 14.08% | 6.97% | 0.50x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
PTCT Options Activity & IV Rank
PTCT IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 48.7%
7-DTE IV: 49.5%
Expected Move: $5.67
7-DTE Move: $5.67
Days to Exp: 21 (2026-11-20)
Options Flow
Call Volume: 15
Put Volume: 23
P/C Volume: 1.533
BEARISH
Call OI: 659
Put OI: 658
P/C OI: 0.998
Total OI: 1,317
ATM Options Pricing
ATM Call: $3.00
ATM Put: $2.67
Call %: 5.0%
Put %: 4.5%
Chain Summary
Chain Volume: 1,776
Chain OI: 27,322
Last Updated: 10/30/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 0th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
0%
vs own history
GEX tilt
-0.93
OI-weighted, today
Vanna tilt
-0.40
δ-sensitivity to IV
Charm tilt
+0.53
δ-decay vs time
Vanna tilt -0.40: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.53: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 9 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 30 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 30 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)23.3LowOct 30
IV Rank (30 DTE)17.5LowOct 30
Straddle Price (30 DTE)$5.67Oct 30
Beta Analysis
Risk Metrics
Beta: 0.7872
Alpha: -13.27%
Correlation: 0.2432
R-Squared: 5.9%
Stock Volatility: 41.4%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own PTCT
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $61.0M | #595 of 6285 | +94.1% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $59.0M | #279 of 3138 | +35.7% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $24.7M | #420 of 4729 | -21.4% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $3.8M | #2223 of 3716 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
PTCT Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 89,902,644 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
7 filers$64.69M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | $53.84M | 83.22% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $5.00M | 7.73% | 2026-06-30 |
| 3 | Caption Management, LLC | $2.45M | 3.78% | 2026-06-30 |
| 4 | Verition Fund Management LLC | $1.63M | 2.52% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $856.49K | 1.32% | 2026-06-30 |
| 6 | Citadel Advisors LLC Custodian | $530.21K | 0.82% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $388.16K | 0.60% | 2025-09-30 |
4 filers$9.85M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $3.53M | 35.84% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $2.85M | 28.97% | 2026-06-30 |
| 3 | Caption Management, LLC | $2.45M | 24.83% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $1.02M | 10.35% | 2026-06-30 |
PTCT Insider Trading (Form 4)
Latest: 2026-10-16Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-16 | Michael Schmertzler | Director | Sell (S) | −2,500 | $59.61 | -$149.0K | EDGAR |
| 2026-10-13 | Mark Elliott Boulding | EXEC. VP AND CLO | Mixed | — | $51.84 | -$4.8K | EDGAR |
| 2026-10-09 | Michael Schmertzler | Director | Sell (S) | −2,500 | $63.39 | -$158.5K | EDGAR |
| 2026-10-07 | Mark Elliott Boulding | EXEC. VP AND CLO | Mixed | — | $51.74 | -$51.1K | EDGAR |
| 2026-10-02 | Glenn Jr Md Phd Steele | Director | Mixed | — | $38.20 | -$647.2K | EDGAR |
| 2026-09-18 | Michael Schmertzler | Director | Sell (S) | −20,000 | $67.49 | -$1.35M | EDGAR |
| 2026-09-11 | Michael Schmertzler | Director | Sell (S) | −20,000 | $67.59 | -$1.35M | EDGAR |
| 2026-08-28 | Michael Schmertzler | Director | Sell (S) | −25,000 | $72.26 | -$1.81M | EDGAR |
| 2026-08-21 | Michael Schmertzler | Director | Sell (S) | −25,000 | $72.22 | -$1.81M | EDGAR |
| 2026-08-19 | Mark Elliott Boulding | EXEC. VP AND CLO | Mixed | — | $49.13 | -$131.9K | EDGAR |
| 2026-08-06 | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Sell (S) | −10,292 | $68.57 | -$705.7K | EDGAR |
| 2026-08-06 | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Sell (S) | −10,292 | $68.57 | -$705.7K | EDGAR |
| 2026-07-30 | Hege Elisabeth Sollie-Zetlmayer | Director | Award (A) | +6,000 | — | EDGAR | |
| 2026-07-16 | Pierre Gravier | CHIEF FINANCIAL OFFICER | Sell (S) | −3,494 | $80.35 | -$280.7K | EDGAR |
| 2026-07-13 | Mary L. Smith | Director | Mixed | — | $66.47 | -$745.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
PTCT Insider Holdings
18 insiders · @ $59.97
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Michael Schmertzler | Director | 1,454,860 | $87.25M | $4.18M | 31 | 2026-10-16 |
| 2 | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | 383,868 | $23.02M | -$8.62M | 34 | 2026-08-06 |
| 3 | Mark Elliott Boulding | EXEC. VP AND CLO | 105,272 | $6.31M | -$40.35M | 58 | 2026-10-13 |
| 4 | Eric Pauwels | CHIEF BUSINESS OFFICER | 90,977 | $5.46M | -$12.62M | 36 | 2026-06-12 |
| 5 | Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 89,885 | $5.39M | -$10.61M | 41 | 2026-06-22 |
| 6 | Pierre Gravier | CHIEF FINANCIAL OFFICER | 83,986 | $5.04M | -$772.8K | 11 | 2026-07-16 |
| 7 | Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | 79,115 | $4.74M | -$1.38M | 14 | 2026-04-06 |
| 8 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 63,198 | $3.79M | -$45.79M | 58 | 2026-07-13 |
| 9 | Hege Elisabeth Sollie-Zetlmayer | Director | 52,526 | $3.15M | $0 | 1 | 2026-07-30 |
| 10 | Glenn Jr Md Phd Steele | Director | 34,500 | $2.07M | -$1.70M | 13 | 2026-10-02 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
PTCT Board & Officers
As of SEC filings through Oct 16, 2026Directors 11
- Allan Steven Jacobson · since Jun 19, 2013
- David P Southwell · since Jun 19, 2013
- Jerome B Zeldis · since Jun 19, 2013
- Michael Schmertzler · since Jun 19, 2013
- Glenn Jr Md Phd Steele · since Jun 10, 2015
- Emma Reeve · since Dec 14, 2018
- Stephanie Okey · since Dec 14, 2018
- Mary L. Smith · since Jun 8, 2021
- Matthew B. Klein · listed since Dec 2023
- Jessica Caroline Chutter · since Mar 24, 2026
- Hege Elisabeth Sollie-Zetlmayer · since Jul 28, 2026
Officers 7
- Matthew B. Klein · Chief Executive Officer · listed since Apr 2023
- Pierre Gravier · Chief Financial Officer · since Jul 13, 2023
- Neil Gregory Almstead · Chief Technical Ops Officer · listed since Jan 2019
- Christine Marie Utter · SVP, Chief Accounting Officer · listed since Feb 2024
- Lee Scott Golden · EVP & Chief Medical Officer · listed since Apr 2024
- Eric Pauwels · Chief Business Officer · listed since Mar 2025
- Mark Elliott Boulding · Exec. VP and CLO · since Jun 19, 2013
Changes in the last 10 years (32)
| Jul 28, 2026 | Hege Elisabeth Sollie-Zetlmayer became a director |
| Jun 8, 2026 | The company announced the departure of Alethia Young from the board in an SEC filing |
| Mar 24, 2026 | Jessica Caroline Chutter became a director |
| Mar 18, 2025 | Eric Pauwels listed as Chief Business Officer (previously Chief Executive Officer) in SEC filings |
| Jan 7, 2025 | Eric Pauwels no longer listed as a director in SEC filings |
| Apr 19, 2024 | Eric Pauwels listed as Chief Executive Officer (previously Chief Business Officer) in SEC filings |
| Apr 19, 2024 | Eric Pauwels first listed as a director in an SEC filing |
| Apr 4, 2024 | Lee Scott Golden listed as EVP & Chief Medical Officer (previously Chief Medical Officer) in SEC filings |
| Feb 1, 2024 | Christine Marie Utter listed as SVP, Chief Accounting Officer (previously SVP, Finance & CAO) in SEC filings |
| Dec 28, 2023 | Matthew B. Klein first listed as a director in an SEC filing |
| Jul 13, 2023 | Pierre Gravier became Chief Financial Officer |
| Jun 6, 2023 | William F. Bell Jr. became a director |
| Jun 6, 2023 | Lee Scott Golden became Chief Medical Officer |
| May 20, 2023 | The company announced the departure of Emily Luisa Hill as Chief Financial Officer in an SEC filing |
| Apr 20, 2023 | Matthew B. Klein listed as Chief Executive Officer (previously Chief Operating Officer) in SEC filings |
| Mar 22, 2023 | The company announced the departure of Stuart Walter Peltz from the board in an SEC filing |
| Mar 22, 2023 | The company announced the departure of Stuart Walter Peltz as Chief Executive Officer in an SEC filing |
| Dec 5, 2022 | The company announced the departure of Dawn Svoronos from the board in an SEC filing |
| Jun 8, 2022 | Alethia Young became a director |
| Jan 11, 2022 | Matthew B. Klein listed as Chief Operating Officer (previously Chief Development Officer) in SEC filings |
| Jun 8, 2021 | Mary L. Smith became a director |
| Apr 16, 2020 | Matthew B. Klein became Chief Development Officer |
| Apr 16, 2020 | Eric Pauwels became Chief Business Officer |
| Jul 2, 2019 | Christine Marie Utter listed as SVP, Finance & CAO (previously Principal Financial Officer) in SEC filings |
| May 31, 2019 | Emily Luisa Hill became Chief Financial Officer |
| Jan 9, 2019 | Neil Gregory Almstead listed as Chief Technical Ops Officer (previously EVP Research Pharma Ops & Tech) in SEC filings |
| Dec 14, 2018 | Stephanie Okey became a director |
| Dec 14, 2018 | Emma Reeve became a director |
| Jun 2, 2017 | Christine Marie Utter became Principal Financial Officer |
| May 31, 2017 | Marcio Souza became Chief Operating Officer |
| May 2, 2017 | Complete Pharma Holdings II, LLC reported in an SEC filing no longer being a 10% owner |
| Apr 20, 2017 | Complete Pharma Holdings II, LLC became a 10% owner |
Not reported recently (8)
- William F. Bell Jr. · Last reported as a director in an SEC filing dated Feb 16, 2024
- Marcio Souza · Last reported as Chief Operating Officer in an SEC filing dated Feb 12, 2020
- Mark Rothera · Last reported as Chief Commercial Officer in an SEC filing dated May 25, 2017
- Shane William Charles Kovacs · Last reported as Chief Financial Officer in an SEC filing dated May 11, 2017
- Cameron Geoffrey McDonough · Last reported as a director in an SEC filing dated Jan 5, 2017
- Adam Koppel · Last reported as a director in an SEC filing dated Jan 5, 2017
- Ronald C Renaud JR · Last reported as a director in an SEC filing dated Jan 5, 2017
- Tuyen Ong · Last reported as Chief Medical Officer in an SEC filing dated Jan 5, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
PTCT Proposed Insider Sales (Form 144)
Latest: 2026-10-09
? Form 144 Guide
Last 30d:
5 filings
· $1.6M notice value
· Last 90d:
9 filings
· $8.9M notice value
· 4 unique filers
· 89% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Section Six Partners, L.P. (3, $7.0M) · STEELE GLENN JR MD PHD (1, $782K) · Klein Matthew B. (1, $706K) · Boulding Mark Elliott (4, $347K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-09 | Boulding Mark Elliott | Officer | 192 | $12.3K | 2026-10-09 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-10-07 | Section Six Partners, L.P. | Affiliate of Director | 10,000 | $643.5K | 2026-10-07 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-10-06 | Boulding Mark Elliott | Officer | 435 | $27.9K | 2026-10-06 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-10-05 | Boulding Mark Elliott | Officer | 1,638 | $104.9K | 2026-10-05 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-09-30 | STEELE GLENN JR MD PHD | Director | 12,000 | $781.9K | 2026-09-30 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-09-09 | Section Six Partners, L.P. | Affiliate of Director | 40,000 | $2.74M | 2026-09-09 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-08-25 144/A | Section Six Partners, L.P. | Affiliate of Director | 50,000 | $3.65M | 2026-08-19 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-08-17 | Boulding Mark Elliott | Officer | 2,813 | $201.7K | 2026-08-17 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-08-04 | Klein Matthew B. | Officer, Director | 10,292 | $705.8K | 2026-08-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-07-14 | Gravier Pierre | Officer | 3,494 | $280.7K | 2026-07-14 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
124 ETFs hold PTCT
25 shown · $1.41B total exposure · 0.23% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.30% | $323.7M | $105.6B | 2026-10-29 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $163.9M | — | 2026-09-30 |
| 3 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.37% | $147.3M | $10.8B | 2026-10-29 |
| 4 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.18% | $135.5M | $75.5B | 2026-10-29 |
| 5 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.07% | $115.7M | — | 2026-09-30 |
| 6 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.15% | $64.4M | — | 2026-09-30 |
| 7 | VXF Vanguard Extended Market ETF | Vanguard | 0.07% | $61.0M | — | 2026-09-30 |
| 8 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.30% | $49.2M | $16.2B | 2026-10-29 |
| 9 | IJT iShares S&P Small-Cap 600 Growth ETF | iShares (BlackRock) | 0.64% | $48.6M | $7.5B | 2026-10-29 |
| 10 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.30% | $42.9M | $14.0B | 2026-10-29 |
| 11 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.35% | $40.1M | $11.5B | 2026-10-29 |
| 12 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.18% | $31.2M | — | 2026-09-30 |
| 13 | SLYG State Street® SPDR® S&P 600™ Small Cap Growth ETF | SPDR (State Street) | 0.64% | $30.7M | $4.8B | 2026-10-29 |
| 14 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.13% | $28.5M | — | 2026-05-31 |
| 15 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.31% | $19.1M | — | 2026-09-30 |
| 16 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.05% | $17.3M | — | 2026-10-29 |
| 17 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.21% | $14.6M | $6.9B | 2026-10-29 |
| 18 | VHT Vanguard Health Care ETF | Vanguard | 0.06% | $13.9M | — | 2026-09-30 |
| 19 | PSC Principal U.S. Small-Cap ETF | Nport | 0.47% | $11.0M | — | 2026-06-30 |
| 20 | PBE Invesco Biotechnology & Genome ETF | Invesco | 2.28% | $10.2M | — | 2026-10-29 |
| 21 | JSMD Janus Henderson Small/Mid Cap Growth Alpha ETF | Janus | 0.98% | $10.1M | — | 2026-10-30 |
| 22 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $9.5M | — | 2026-10-29 |
| 23 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.05% | $7.3M | $14.1B | 2026-10-29 |
| 24 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.01% | $7.1M | $95.5B | 2026-10-29 |
| 25 | VIOG Vanguard S&P Small-Cap 600 Growth ETF | Vanguard | 0.64% | $6.8M | — | 2026-10-29 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.06
TTM Revenue
$1.16B
TTM Net Income
$-105.97M
TTM Op. Cash Flow
$10.49M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $357.81M | $-51.69M | $-0.62 | $-25.31M |
| Q2 '26 | 2026-06-30 | $360.52M | $83.50M | $0.92 | $129.11M |
| Q1 '26 | 2026-03-31 | $272.55M | $-2.81M | $-0.03 | $-59.04M |
| Q4 '25 | 2025-12-31 | $164.68M | $-134.97M | $-1.67 | $-34.27M |
| Q3 '25 | 2025-09-30 | $211.01M | $15.90M | $0.20 | $-66.30M |
| Q2 '25 | 2025-06-30 | $178.88M | $-64.85M | $-0.83 | $-58.33M |
| Q1 '25 | 2025-03-31 | $1.18B | $866.56M | $10.04 | $870.10M |
| Q4 '24 | 2024-12-31 | $213.17M | $-65.89M | $-0.85 | $-30.00M |
| Q3 '24 | 2024-09-30 | $196.79M | $-106.65M | $-1.39 | $-76.99M |
| Q2 '24 | 2024-06-30 | $186.70M | $-99.18M | $-1.29 | $-71.45M |
| Q1 '24 | 2024-03-31 | $210.12M | $-91.58M | $-1.20 | $70.76M |
| Q4 '23 | 2023-12-31 | $307.06M | $-155.79M | $-2.06 | $-225.29M |
Q3 2026 • period ending 2026-09-30 • filed 2026-10-29
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
5.20
EV/EBITDA
27.38
EV/Sales
4.69
ROE
—
ROA
-1.2%
Div Yield
0.00%
FCF Yield
-0.58%
Debt/Equity
—
Current Ratio
—
Market Cap
$5.25B
as of 2026-10-30
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
8.30M
SI % of Float
10.47%
Days to Cover
7.59
Short Vol Ratio
48.3%
Free Float
79.27M
Float %
95.0%
Short interest 2026-10-15 • Short volume 2026-10-30 • Float 2026-09-22